Valuation
- Market cap
- 222,192,000
- Revenue TTM
- $65,320,000
- Net income TTM
- $-81,890,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -125.37%
- Debt to equity
- 0.00
Trading
- Volume
- 457,600
- Avg volume
- 297,610
- Day's range
- $7.56 – $8.06
- Shares out
- 29,159,000
- Stochastic %K
- 1%
- Beta
- 0.75
- Analysts
- Strong Buy
- Price target
- $19.50
Company profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; E...
Show more
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 607 0800
- Website
- https://www.enanta.com
- Address
- 4 Kingsbury Avenue, Watertown, United States
Latest news
No headlines yet.